RIGL Rigel Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RIGL

Price (delayed)

$1.13

Market cap

$198.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$225.97M

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare ...

Highlights
Rigel Pharmaceuticals's EPS has surged by 59% YoY
RIGL's equity has plunged by 110% YoY but it is up by 10% from the previous quarter
The net income has surged by 57% year-on-year but it has declined by 2.7% since the previous quarter
RIGL's debt is up by 46% YoY
The company's gross profit fell by 15% QoQ and by 7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rigel.com
Peers: AZN SGMO XOMA AMGN

Key stats

What are the main financial stats of RIGL
Market
Shares outstanding
175.38M
Market cap
$198.18M
Enterprise value
$225.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
Earnings
Revenue
$116.88M
EBIT
-$18.22M
EBITDA
-$16.98M
Free cash flow
-$5.48M
Per share
EPS
-$0.14
Free cash flow per share
-$0.03
Book value per share
-$0.16
Revenue per share
$0.67
TBVPS
$0.59
Balance sheet
Total assets
$117.23M
Total liabilities
$145.87M
Debt
$60.58M
Equity
-$28.64M
Working capital
$46M
Liquidity
Debt to equity
-2.11
Current ratio
1.86
Quick ratio
1.64
Net debt/EBITDA
-1.64
Margins
EBITDA margin
-14.5%
Gross margin
93.9%
Net margin
-21.5%
Operating margin
-17.5%
Efficiency
Return on assets
-21.2%
Return on equity
N/A
Return on invested capital
-24.2%
Return on capital employed
-28.5%
Return on sales
-15.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
-0.88%
1 week
1.8%
1 month
-20.42%
1 year
-3%
YTD
-22.07%
QTD
-23.65%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$116.88M
Gross profit
$109.77M
Operating income
-$20.49M
Net income
-$25.09M
Gross margin
93.9%
Net margin
-21.5%
RIGL's operating income has surged by 63% year-on-year
The operating margin has soared by 62% YoY but it has contracted by 14% from the previous quarter
The net income has surged by 57% year-on-year but it has declined by 2.7% since the previous quarter
RIGL's net margin has soared by 56% YoY but it is down by 16% QoQ

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
Rigel Pharmaceuticals's EPS has surged by 59% YoY
RIGL's equity has plunged by 110% YoY but it is up by 10% from the previous quarter
The stock's price to sales (P/S) is 54% less than its 5-year quarterly average of 3.6 and 7% less than its last 4 quarters average of 1.8
Rigel Pharmaceuticals's revenue has decreased by 12% QoQ and by 2.8% YoY

Efficiency

How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 66% YoY but it has decreased by 12% QoQ
RIGL's return on invested capital has surged by 63% year-on-year and by 3.2% since the previous quarter
The return on assets has surged by 52% year-on-year but it has declined by 7% since the previous quarter

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 20% less than its total liabilities
Rigel Pharmaceuticals's total assets has decreased by 13% YoY
The quick ratio has grown by 9% YoY but it has contracted by 8% from the previous quarter
RIGL's equity has plunged by 110% YoY but it is up by 10% from the previous quarter
RIGL's debt is up by 46% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.